Free fatty acid receptor 2 (FFAR2, also named GPR43), is activated by short-chain fatty acids (SCFAs), such as butyrate, that are produced when gut bacteria ferment dietary fiber. FFAR2 has been suggested to regulate colonic inflammation, which is a major risk factor for the development of colon cancer and is also linked to epigenetic dysregulation in colon carcinogenesis. The current study assessed whether FFAR2, acting as an epigenetic regulator, protects against colon carcinogenesis. To mimic the mild inflammation that promotes human colon cancer, we treated mice with dextran sodium sulfate (DSS) overnight, which avoids excessive inflammation but induces mild inflammation that promotes colon carcinogenesis in the Apc Min/1 and the azoxymethane (AOM)-treated mice. Our results showed that FFAR2 deficiency promotes the development of colon adenoma in the Apc
Introduction
Free fatty acid receptor 2 (FFAR2, also known as GPR43) belongs to the G protein-coupled receptor (GPCR) family. 1 GPCRs span the cell membrane seven times, and they signal via heterotrimeric G proteins of a and bg subunits to activate various downstream effectors. 1 FFAR2 is activated by shortchain fatty acids (SCFAs), such as butyrate, that are produced when gut bacteria ferment dietary fiber. 1 Activated FFAR2 couples to the Gai pathway to inhibit cAMP signaling, and to the Gaq pathway to promote calcium mobilization. 1 cAMP signaling dampened by FFAR2 then suppresses protein kinase A (PKA, a primary downstream effector of cAMP) and its substrate, cAMP response element binding protein (CREB). The net result is a decrease in histone deacetylase (HDAC) expression. 2 SCFAs, which are naturally occurring ligands for FFAR2, suppress class I HDACs (HDAC1, 2, 3, 8) and class IIa HDACs (HDAC4, 5, 7, 9). 3, 4 The two major signaling mechanisms of SCFA-mediated functions are inhibition of HDACs and activation of GPCRs.
5
FFAR2 expression is higher in normal colonic epithelium and neutrophils than in other immune cells. 6, 7 Several lines of evidence suggest that FFAR2 is an important regulator of colonic inflammation. Stimulation of FFAR2 by SCFAs is necessary for normal resolution of certain inflammatory responses, because FFAR2-deficient mice showed exacerbated inflammation in a colitis model. 7 Regulatory T cells (Tregs) that express the transcription factor Foxp3 are critical for regulating intestinal inflammation. 6 FFAR2-deficient mice exhibit a larger and dysfunctional Treg pool, and they developed more severe colitis. 6 Compared to wild-type (WT) mice, dextran sodium sulfate (DSS)-treated FFAR2-deficient mice had significantly worsened colonic inflammation, and higher levels of tumor necrosis factor alpha (TNF-a) and interleukin 17 (IL-17) protein in their colonic mucosa. 8 In addition, dysregulated inflammasome contributed to exacerbated colitis in the FFAR2-deficient mice. 9 Accordingly, these studies suggest that FFAR2 plays a crucial role in suppressing colonic inflammation. However, it remains unclear whether FFAR2 acts as an epigenetic regulator that protects against colon carcinogenesis. The mechanisms by which histone modifications and DNA methylation suppress gene transcription have been elucidated. 10 Methylated CpG islands form binding sites for proteins, such as MeCp2, that bind to methylated DNA. Binding to MeCp2 is followed by recruitment of a protein complex that includes HDACs. This process ultimately leads to a closed chromatin configuration that excludes transcription factors. Evidence suggests that histone H3 lysine 9 methylation (H3K9me) and H3K27 tri-methylation (H3K27me3) are critical histone modifications that associate with closed chromatin at DNA methylation sites.
10
In the current study, we slightly irritated colon by only using overnight DSS treatment and successfully promoted 100% colon tumor incidence in the Apc Min/1 mice and the azoxymethane (AOM)-treated mice on C57/B6 background.
11
These models mimic mild inflammation in human colorectal cancer. We investigated the role of FFAR2 in colon adenoma development in the Apc Min/1 /DSS mice. We also assessed whether loss of FFAR2 promoted the progression of adenoma to adenocarcinoma in the AOM/DSS mice. We found that loss of FFAR2 promoted the development of colon adenoma and the progression of adenoma to adenocarcinoma. FFAR2 deficiency led to enhanced downstream cAMP-PKA-CREB pathway, which resulted in overexpression of HDACs and epigenetically decreased levels of inflammation suppressors.
Materials and Methods

Animals and reagents
All the animal protocols followed the institutional guidelines for animal care and were approved by the Medical College of Wisconsin Animal Care and Use Committee. Breeding pairs of the Apc Min/1 mice (C57/B6 background) were purchased from the Jackson Laboratory (Bar Harbor, ME), and breeding pairs of the FFAR2 heterozygous (FFAR2 Immunohistochemistry FFPE colon tissue blocks were cut into 4 lm sections, and immunohistochemistry was conducted as previously described. 12, 13 A Dako Autostainer was used to stain the slides with primary antibodies to PKA (phospho S99; 1:1000, ab32390), CREB (phospho S133; 1:500, ab32096), and GR-1 (1:50, ab2557) from Abcam (Cambridge, MA); antibodies to cAMP (1:250, LS-C121425) from LifeSpan Biosciences (Seattle, WA); antibodies to HDAC2 (1:100, sc-7899) from Santa Cruz Biotechnology (Dallas, TX); antibodies to HDAC4 (1:800, NBP2-22151) from Novus Biologicals (Littleton, CO); and antibodies to Ki67 (1:300, 12202) from Cell Signaling Technology (Danvers, MA). Stained slides were photographed at 203 magnification, and only the staining in the adenoma and adenocarcinoma area was quantified, as previously described. 12, 13 Isolation of colonic lamina propria Colonic lamina propria (LP) was prepared using a Dissociation Kit (130-097-410) from Miltenyi Biotec (San Diego, CA) according to the instructions of the manufacturer. Briefly, colon specimens were collected, open longitudinally, and cut into short segments. All the segments were incubated in predigestion solution at 378C for 20 min twice, followed by incubation in HBSS without calcium. Then all the segments were incubated in preheated digestion solution with enzyme mix at 378C for 30 min. The gentle MACs dissociator (m_intestine_01 program) was run to mechanically brake down tissue segments. Samples were centrifuged and the pellet was resuspended in RPMI 1640 medium for further application. 13 
Isolation of colonic epithelium
Two weeks after the DSS treatment, subgroups of the WT and FFAR2 2/2 mice, were euthanized by CO 2 . Colonic epithelium was prepared by incubation with chelating agents (PBS containing 20 mM EDTA) as previously described. 14 
Butyrate treatment
Colonic epithelium and colonic LP were prepared and cultured in DMEM containing 10% FBS. These cultured cells were treated with 5 mM butyrate for 16 hr. The cells were collected for further application.
Flow cytometry
The samples were first stained with CD45 and GR-1 antibodies (BD Biosciences, Franklin Lakes, NJ). Then the samples were fixed and permeabilized by Cytofix/Cytoperm (BD Biosciences). The samples were stained with IL-1, IL-6, and TNF antibodies (BD Biosciences). The samples were analyzed on a LSRII flow cytometer (BD Biosciences), and the results were analyzed using the FlowJo software (Tree Star, Ashland, OR).
Chromatin immunoprecipitation-quantitative PCR analysis (ChIP-qPCR)
Chromatin in colonic LP samples was immunoprecipitated, using a ChIP-IT High Sensitivity Kit (53040) from Active Motif (Carlsbad, CA) according to the manufacturer's instructions. Sonicated chromatin was incubated overnight with antibodies to H3K27me3 (ab6002) and H3K4me3 (ab8580) from Abcam (Cambridge, MA). Quantitative PCR analysis was performed after the ChIP assay, and the percentage enrichment of the input was analyzed on the promoter regions of gapdh, sfrp1, sox17, dkk2, dkk3, vdr, adh1, and socs1 genes. Primer information is provided in Supporting Information Table S1a .
Quantitative PCR analysis
We extracted RNA from FFPE mouse colon tissues, using the RecoverAll Total Nucleic Acid Isolation Kit for formalinfixed and paraffin-embedded tissues (Ambion, Grand Island, NY). RNA from butyrate-treated colonic epithelium and colonic LP samples were extracted using AllPrep DNA/RNA/ Protein Mini kit (Qiagen, Venlo, Netherlands). Total RNA was reverse-transcribed using Superscript III RT (Invitrogen, Grand Island, NY), and quantitative PCR procedures were performed. Primer information is provided in Supporting Information Table S1b .
Pyrosequencing
Genomic DNA from butyrate-treated colonic epithelium and colonic LP samples were extracted using AllPrep DNA/RNA/ Protein Mini kit (Qiagen, Venlo, Netherlands). 500 ng of the genomic DNA was treated with sodium bisulfite, and purified using the EZ DNA Methylation kit (Zymo Research, Orange, CA). Bisulfite-treated DNA was amplified with specific primers of sox17 and socs1 genes. Primer information is provided in Supporting Information Table S1c . A Pyrosequencing system (Qiagen, Valencia, CA) was used to measure
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Results
FFAR2 deficiency promoted the development of colon adenomas and the progression of adenoma to adenocarcinoma, and enhanced the downstream cAMP-PKA-CREB-HDAC pathway
We successfully manipulated the dose and duration of DSS treatment to only slightly irritate colon, which mimic the mild inflammation that promotes the development of adenomas and adenocarcinoma in human colon.
11 Four-to five-week-old Apc Min/1 mice and Apc Min/1 -FFAR2 2/2 mice were exposed to 5% DSS overnight (Fig. 1a) . Six weeks after the DSS treatment, 100% mice had developed colon lesions. The Apc Min/1 -FFAR2 /DSS mice, staining for cAMP-PKA-CREB-HDAC signaling and the proliferative marker Ki67 was enhanced compared to those of the Apc Min/1 /DSS mice (Fig. 1c) .
In another model, we also examined the role of FFAR2 in the progression of colon adenoma to carcinoma that results from mild inflammation caused by AOM and overnight DSS treatment. We first injected 5-to 6-week-old WT and FFAR2 2/2 mice (on the C57/B6 background) with one dose of AOM (15 mg/kg, body weight) and then treated them with 5% DSS overnight (Fig. 1d) . The FFAR2 2/2 mice had significantly more and larger lesions in the colon, and a higher percentage of them developed intramucosal adenocarcinoma (Fig. 1e) , as well as overexpressed cAMP-PKA-CREB-HDAC signaling and Ki67 staining (Fig. 1f) compared to the WT mice. Together, these results indicate that FFAR2 protects against colon carcinogenesis. In the absence of FFAR2, the downstream cAMP-PKA-CREB-HDAC signaling was enhanced, which contributed to the increased proliferation.
FFAR2 deficiency disrupted neutrophil homeostasis in colonic lamina propria FFAR2 has a higher expression in neutrophils than other immune cells. We further investigate if FFAR2 deficiency influences neutrophil homeostasis. We stained the colon tissues with anti-GR-1 antibodies to determine the neutrophil infiltration, and measured the neutrophil population and its cytokine production by flow cytometry. We observed a significantly increased neutrophil infiltration to colon adenomas (Fig. 1c) and a higher neutrophil population in colonic LP of the Apc Min/1 -FFAR2 2/2 /DSS mice compared to Apc Min/1 /DSS mice (Fig. 2a,b and Supplementary Fig. 1a ). In addition, the levels of IL-1b, IL-6, and TNF-a were significantly enhanced by FFAR2 deficiency (Fig. 2b and Supporting Information Fig.  S1a) . We further depleted neutrophils by injecting anti-GR-1 antibodies to the Apc
/DSS mice (Fig. 2c) and confirmed the depletion in splenocytes by flow cytometry (Supporting Information Fig. S1b) . Neutralization of neutrophils significantly decreased the number and size of colon tumors driven by FFAR2 deficiency (Fig. 2d) .
Similarly, we observed an increased infiltration of neutrophils in adenomas and adenocarcinomas of the AOM/DSStreated FFAR2 2/2 mice (Fig. 1f) . However, the levels of colonic LP neutrophils, IL-1b, IL-6, and TNF-a remained unchanged between the WT mice and the FFAR2 2/2 mice (Fig. 2e,f and Supporting Information Fig. S1a ).
FFAR2 deficiency changed histone modification on the inflammation regulators
Since we observed overexpression of HDACs in the FFAR2-deficient mice (Fig. 1) , we then studied epigenetic changes induced by loss of FFAR2 in the inflammation regulators. Colonic LP from the Apc Min/1 /DSS mice and Apc Min/1 -FFAR2 2/2 /DSS mice was analyzed by ChIP-qPCR (Fig. 3a) . Binding of H3K27me3, a suppressive histone mark, was enhanced on the promoter regions of sfrp1 in colonic LP of the Apc
/DSS mice (Fig. 3b) . In contrast, binding of H3K4me3, an active histone mark, were lower on the promoter regions of sox17, dkk3, and socs1 in colonic LP of the Apc Min/1 -FFAR2 2/2 /DSS mice (Fig. 3c) . mRNA expression of sfrp1, dkk3, and socs1 was significantly decreased in colon of the Apc Min/1 -FFAR2 2/2 /DSS mice (Fig. 3d) . These results suggest that loss of FFAR2 decreased the expression of inflammation suppressors through changing histone marks on their promoter regions.
We also examined epigenetic changes of the inflammation regulators in the AOM/DSS model (Fig. 3e) . Interestingly, binding of both H3K27me3 and H3K4me3 was enriched on the promoter regions of dkk2, dkk3, vdr, and adh1, which are inflammation suppressors 15, 16 (Fig. 3f,g ). Despite the overexpression of HDACs in the FFAR2 2/2 mice (Fig. 1f) , gene expression of these inflammation suppressors was not changed (Fig. 3h) .
FFAR2 was required for butyrate to function in colonic epithelium and colonic lamina propria
To determine if the FFAR2 pathway became dysregulated, we isolated the colonic epithelium and LP from the AOM/DSStreated WT and FFAR2 2/2 mice 2 weeks after the DSS treatment (Fig. 4a) . We cultured the epithelium and LP with or Cancer Genetics and Epigenetics 
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without 5 mM butyrate for 16 hr, and then harvested the cells. We used butyrate, a ligand for FFAR2, to determine the ligand-receptor axis in the cultured colonic epithelium and LP. Our results showed that mRNA expression of hdac2 in the colonic epithelium (Fig. 4b) and LP (Fig. 4c) was higher in the FFAR2 2/2 mice. It was decreased by butyrate only in the WT mice (Fig. 4b,c) , suggesting that FFAR2 needs to be present for the ligand to function. For inflammation suppressor sox17 and socs1, 15,17 mRNA expression was lower and DNA methylation of the promoters was higher in the FFAR2 2/2 mice (Fig. 4b,c) . Consistent with hdac2, butyrate lost its ability to modulate sox17 and socs1 in the colonic epithelium and LP from the FFAR2 2/2 mice (Fig. 4b,c) . Furthermore, butyrate decreased the percentage of neutrophils and IL-1b levels in colonic LP from the WT mice but not the FFAR2 2/2 mice ( Fig. 4d and Supporting Information Fig.   S2 ). These results again suggest that loss of FFAR2 impairs butyrate's protective effects.
Discussion
The fatty acid receptor family has several members, such as FFAR1 (GPR40), FFAR2 (GPR43), FFAR3 (GPR41), GPR84, and GPR120. FFAR1 and GPR120 respond to long-chain fatty acids; GPR84 is activated by medium-chain fatty acids 18 ; while FFAR2 and FFAR3, sharing 43% of their amino acids in common, are the two main receptors for SCFAs.
19 FFAR3 is expressed in adipose tissue, while FFAR2 is highly expressed in colonic epithelial cells, 20 colonic neutrophils and monocytes. 21, 22 FFAR2 has been reported to be involved in colonic inflammation. 23, 24 However, it remains to be elucidated whether FFAR2 is an epigenetic regulator that suppresses colon tumorigenesis. Our results support the idea that FFAR2 suppresses tumor progression in an epigenetic manner in both the Apc Min/1 /DSS and the AOM/DSS models. FFAR2 deficiency led to overexpression of its downstream cAMP-PKA-CREB-HDAC signaling, which epigenetically dysregulated inflammation suppressors. Our results also showed that neutrophil population in the colonic LP was increased when FFAR2 was knocked out in the Apc Min/1 /DSS model. Infiltration of neutrophils into adenomas and adenocarcinomas was increased in the FFAR2-deficient mice. These results suggest that FFAR2 is important for colon neutrophil homeostasis. More importantly, our results suggest that FFAR2 is a tumor suppressor that blocks progression of lowgrade dysplasia to high-grade dysplasia and further to adenocarcinoma. 
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It should be noted that loss of FFAR2 may affect neutrophil homeostasis and histone modification differently at different stages of colon carcinogenesis. Loss of FFAR2 led to the infiltration of neutrophils in colon tumors in both the Apc Min/1 /DSS and the AOM/DSS mice. Interestingly, knocking out FFAR2 increased the percentage of neutrophils and levels of cytokines in colonic LP from the Apc Min/1 /DSS mice but not in colon from the AOM/DSS mice. These results suggest that neutrophil trafficking induced by FFAR2 deficiency differs at different stages of colon carcinogenesis.
Suppressor genes sfrp1 and dkk3 are key inhibitors in the Wnt/b-catenin pathway. Our previous studies using DSSinduced colitis model showed hypermethylation of the promoter region of sfrp1 and dkk3, suggesting their protective role against colon inflammation.
15
Consistently, sfrp1 and dkk3 were hypermethylated in human CRC 25, 26 and in Apc Min/1 mice. 27 Overexpression of DKK3 suppressed proliferation and invasion, induced apoptosis, and reduced the b-catenin accumulation in colon cancer cells. 28 In addition, SOCS1 is a suppressor of cytokine signaling, and it has been reported to inhibit the reactive oxygen species (ROS)-induced epithelial-mesenchymal transition of colon cancer cells. 29 Overexpression of SOCS1 increased the mir-200 family of miRNAs, which promotes the mesenchymal-epithelial transition and reduces tumor migration in colon cancer cells. 30 These studies demonstrated the crucial role of sfrp1, dkk3, /DSS mice. (e) The wild-type (WT) and FFAR2 2/2 mice were treated with one dose of AOM (15 mg/kg body weight, i.p.) followed by 5% DSS overnight, and were euthanized 6 weeks after the DSS treatment. ChIPqPCR analysis of H3K27me3 (f) and H3K4me3 (g) on the promoter regions of inflammation suppressors (triple technique repeats were shown), and mRNA expression of those genes (h) from colonic LP of the AOM/DSS-treated WT and FFAR2 2/2 mice (n 5 3). *p < 0.05.
and socs1 in gut inflammation and colon carcinogenesis. Our current study demonstrated that FFAR2 deficiency induced differential modifications of H3K27me3 and H3K4me3 on the promoter regions of these inflammation suppressors in colonic LP from both models. Histone modifications correlated better with mRNA expression of inflammation suppressors in the Apc Min/1 /DSS model than in the AOM/DSS model. Despite FFAR2-deficiency enriched binding of both H3K27me3 and H3K4me3 to multiple inflammation suppressors in the AOM/DSS model, mRNA expression of these genes remained unchanged. Therefore, it is possible that these genes are not regulated by histone modifications in the AOM/DSS model. Furthermore, other histone modifications could affect gene expression. For example, enhancer of zeste homolog 2 (EZH2), the functional enzymatic component of the polycomb repressive complex 2 (PRC2), has been shown to directly transfer methyl groups onto H3K27, 31 in turn to silence gene expression. One group observed that HDAC inhibitors prevented the transfer of methyl groups by PRC2 on the promoter region of tumor suppressor gene E-cadherin, which led to increased expression of E-cadherin. 32 Though we did not observe significant change of the overall ezh2 mRNA expression in the FFAR2-deficient mice (Supporting Information Fig. S3 ), whether EZH2-containing PRC2 regulates the H3K27me3 levels on the promotor regions of inflammation suppressors (sfrp1, dkk3, and socs1) in the FFAR2-deficient mice needs further investigation.
SCFAs play essential roles in colonic heath and integrity. For example, butyrate is the major and preferred energy source for colonocytes. 33 SCFAs also regulate colonic mobility, colonic blood flow, and gastrointestinal pH that affects uptake and absorption of electrolytes and nutrients. 34 In addition, SCFAs act on host immune system to elicit antiinflammatory and anti-tumorigenic effects. 35, 36 The two major signaling mechanisms of SCFAs are inhibition of HDACs and activation of GPCRs. 5 SCFAs mediated their anti-tumor effects, including inhibiting cancer cell proliferation and inducing apoptotic cell death, through activating FFAR2 receptors in human colon cancer cells, 37 suggesting that FFAR2 functions as a tumor suppressor in colon cancer cells. Consistently, our previous study 13 and the results from current study also indicate that FFAR2 plays a tumor suppressor role in the mouse models of colon cancer. Furthermore, studies have shown that SCFAs can cross the mucosa by active transports, such as the monocarboxylate transporter 1 (MCT-1) and the sodium-coupled monocarboxylate transporter 1 (SMCT-1), and inhibit HDACs independent of FFAR2. 38, 39 These transporters are highly expressed on colonocytes and along the GI tract, 40 and MCT-1 has high expression on lymphocytes. 41 Therefore, it is possible that both absorption-mediated and FFAR2-mediated HDAC inhibition by SCFAs occur within the same cell. We further knocked down ffar2 in SW480 and HT29 cells, which have relatively higher levels of FFAR2 expression (Supporting 2/2 mice were treated with one dose of AOM (15 mg/kg body weight, i.p.) followed by 5% DSS overnight, and were euthanized 2 weeks after the DSS treatment. Colonic epithelium and LP were isolated from these mice and cultured with or without 5 mM butyrate for 16 hr. mRNA expression of hdac2, sox17, and socs1 and promoter DNA methylation of sox17 and socs1 in colonic epithelium (b) and colonic LP (c) (WT: n 5 6, 
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Information Fig. S4a,b) and measured their HDAC activities upon butyrate treatment. Interestingly, we observed higher levels of HDAC activities in ffar2-knock-down SW480 cells at the baseline (Supporting Information Fig. S4c) , which is consistent with enhanced HDAC expression in our FFAR2-deficient mice. However, butyrate induced similar dosedependent inhibition of HDAC activities in both ffar2-intact and ffar2-knock-down SW480 cells. These results suggest both absorption-mediated and FFAR2-mediated HDAC inhibition by butyrate occur in SW480 cells. By contrast, we did not find significant effects on HDAC activities of HT29 cells by either FFAR2 or butyrate treatment (Supporting Information Fig. S4c) , though other group observed suppressed HDAC activities by butyrate in HT29 cells using nuclear extracts. 42 Recent data suggest that FFAR2 and FFAR3 can form heterodimer, which showed enhanced calcium signaling, lost the ability to inhibit cAMP signaling, but obtained the function to phosphorylate p38 pathway. 43 Though the authors did not observe FFAR2-FFAR3 heterodimers in human colon epithelial cells, 43 we cannot exclude that loss of FFAR2-FFAR3 heterodimer-mediated activities might also contribute to our findings in FFAR2 single knock-out mice. Interestingly, we observed decreased mRNA levels of ffar3 in the FFAR2-deficient mice in the Apc Min/1 /DSS model (Supporting Information Fig. S5 ), while other group found no changes of ffar3 in the FFAR2-deficient mice. 44 Therefore, the reduced expression of ffar3 may also contribute to our observed tumorpromoting effects in the FFAR2-deficient mice. Furthermore, human colon cancer patients have decreased ffar3 mRNA levels when compared to healthy individuals, 45 suggesting its possible tumor suppressor role. The ffar3 gene has very limited CpG islands, suggesting that the epigenetic changes induced by loss of FFAR2 may not directly influence the ffar3 mRNA expression. The mechanism of decreasing ffar3 mRNA expression in the FFAR2-deficient mice of Apc Information Fig. S6 ). NK cells play a critical surveillance role in cancers, including colorectal cancer. 46 In cancer, inducible or adaptive Treg expand, accumulate in tissues and the peripheral blood of patients, and are a functionally prominent component of CD4 1 T lymphocytes. Inducible Treg can produce prostaglandin E 2 (PGE 2 ) and expand in response to tumor antigens and cytokines such as transforming growth factor beta (TGF-b) or IL-10, which are presumed to be responsible for suppressing anti-tumor immune responses and successful tumor escape. 47 Because FFAR2 expression is higher in neutrophils than in other immune cells, 6 we speculate that loss of FFAR2 will have a greater impact on neutrophil function. Indeed, infiltration of neutrophils into colonic LP and colon lesions was enhanced in the FFAR2-deficient mice. However, the decrease in NK cells and increase in CD4
1 T cells undoubtedly contributed to colon tumor development in the knock-out mice as well. Whether unbalanced neutrophil homeostasis then suppresses NK cells and promotes CD4
1 T cells in the FFAR2-deficient mice warrants further investigation.
It also should be noted that studies of FFAR2 and colon inflammation suggest both protective and causative roles. 48 For example, in DSS-induced mouse colitis models, FFAR2 knock-out promoted colon inflammation after either 2.5% DSS for 7 days 7 or 2% DSS for 7 days, 8 suggesting an antiinflammatory role for FFAR2. By contrast, a study that used 4% DSS for 6 days to induce colon colitis reported that FFAR2 knockout suppressed colon inflammation, suggesting a pro-inflammatory role of FFAR2. 49 Therefore, even using the same chemical to induce colitis can give markedly different results, though the reasons for this discrepancy remain to be determined. It is possible that bacteria in different housing environments and the animals could contribute to the degree of colon inflammation induced by DSS. It is also possible that FFAR2 plays different roles with different degrees of inflammation. These results should be interpreted with caution.
Our current study assessed whether FFAR2 deficiency drives the progression of colon cancer that is promoted by mild-inflammation. Our results suggest that FFAR2 is an important epigenetic tumor suppressor that blocks colon cancer progression (Fig. 5) . The downstream pathway of FFAR2, cAMP-PKA-CREB signaling, was overexpressed in the FFAR2-deficient mice, leading to overexpression of HDACs. Consequently, inflammation suppressors were hypermethylated, and their expression levels were decreased. Accordingly, our findings support the hypothesis that FFAR2 is a novel biomarker for colon cancer progression.
